ASCO favors routine KRAS test in colon ca

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 1
Volume 18
Issue 1

SAN FRANCISCO-ASCO released a provisional clinical opinion that recommends routine KRAS testing to guide treatment of metastatic colorectal cancer with cetuximab (Erbitux) and panitumumab (Vectibix).

SAN FRANCISCO-ASCO released a provisional clinical opinion that recommends routine KRAS testing to guide treatment of metastatic colorectal cancer with cetuximab (Erbitux) and panitumumab (Vectibix).

The PCO (www.asco.org/pco/kras) states that all patients with metastatic colon cancer, who have the wild-type form of the gene and who are candidates for anti-EFGR therapy, have their tumors tested.

If a patient has a mutated form of the KRAS gene, the PCO recommends against the use of anti-EFGR antibody therapy. An economic analysis presented at the 2008 ASCO GI Cancers Symposium found that routine testing for KRAS gene mutations could save the U.S. health system up to $604 million per year in the cost of cetuximab alone.

Recent Videos
Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.
Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.
Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.